Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.60 |
| ▸ | SLC5A1 | P13866 | 17/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27799418 | 1.00 | SLC5A2 (0.60) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL25334198 | 0.88 | SLC5A2 (0.64) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL29047384 | 0.88 | SLC5A2 (0.64) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL29047386 | 0.88 | SLC5A2 (0.64) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL48181 | 0.86 | SLC5A2 (0.60) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL27799397 | 0.86 | SLC5A2 (0.60) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL3680627 | 0.85 | SLC5A2 (0.62) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13445671 | 0.81 | SLC5A2 (0.46) | SLC5A2SLC5A1 | |
| SCHEMBL13445669 | 0.77 | SLC5A2 (0.47) | SLC5A2SLC5A1 | |
| SCHEMBL7904604 | 0.75 | SLC5A2 (1.00) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000816-A1 | SODIUM-GLUCOSE LINKED TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE, HYPERTENSION, AND HEART FAILURE IN COMPANION ANIMALS | INCREVET, INC. | 2023-01-05 | — | — | US | disclosed |
| EP-2230907-B1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | THERACOS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2230907-B1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | THERACOS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-8129434-B2 | Benzylphenyl cyclohexane derivatives and methods of use | THERACOS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129434-B2 | Benzylphenyl cyclohexane derivatives and methods of use | THERACOS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129434-B2 | Benzylphenyl cyclohexane derivatives and methods of use | THERACOS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110077212-A1 | THERAPEUTIC USES OF SGLT2 INHIBITORS | THERACOS, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077212-A1 | THERAPEUTIC USES OF SGLT2 INHIBITORS | THERACOS, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| EP-2230907-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | Theracos, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090156516-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | SEED, BRIAN | 2009-06-18 | — | — | US | disclosed |
| US-20090156516-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | SEED, BRIAN | 2009-06-18 | — | — | US | disclosed |
| US-20090156516-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | SEED, BRIAN | 2009-06-18 | — | — | US | disclosed |
| WO-2009076550-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009076550-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077212-A1 | THERAPEUTIC USES OF SGLT2 INHIBITORS | SLC5A2, SLC5A1, PPARG | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 157/4885 |
| US-20090156516-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A8 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 869/4885 |
| US-20230000816-A1 | SODIUM-GLUCOSE LINKED TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE, HYPERTENSION, AND HEART FAILURE IN COMPANION ANIMALS | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.